Search Results
48 Results Found for “vagus nerve stimulation”
In this year-end review, we are pleased to share personal highlights from members of the touchNEUROLOGY Editorial Board, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
The International League Against Epilepsy (ILAE) is a leading global organisation devoted to epilepsy research, education, advocacy and care. Founded in 1909, it now comprises more than 120 national chapters worldwide and serves as a premier resource for clinicians, scientists and public-health ...
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Epilepsy affects approximately 1% of the global population, with one-third of patients remaining refractory to medical therapy.1 Drug-resistant epilepsy (DRE), defined as the failure of two appropriately chosen antiseizure medications (ASMs) to achieve seizure freedom, poses significant risks, including injury and ...
Neuromodulation is a recent technique that has increasingly been used for the abortive and preventive treatment of migraine and other primary headache disorders.1 It has previously been found to be helpful in the treatment of other neurological illnesses, such as ...
Prof. Marc A. Russo President, International Neuromodulation Society Director of Hunter Pain Specialists, Hamilton Day Surgery Centre, Genesis Research Services, Broadmeadow, Australia Co-Director, Innervate Pain Management Program, Newcastle, Australia The 15th World Congress of the International Neuromodulation Society (INS) ...
Parkinson’s disease (PD) is a progressive, neurodegenerative movement disorder and the second most common neurodegenerative disorder in the United States.1 In 2020, approximately 930,000 people in the United States aged 45 years and older developed the disease, and this number is expected ...
Proceedings of a symposium presented at the 13th European Congress of Epileptology, Vienna, 26th August 2018, sponsored by LivaNova. The management of patients with drug-resistant epilepsy (DRE) or treatment-resistant depression (TRD) remain serious challenges. Both conditions are common; epilepsy is believed ...
Sudden unexpected death in epilepsy (SUDEP) is defined as a sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning death in a patient with epilepsy, with or without evidence of a seizure, excluding documented status epilepticus, in which post-mortem examination ...
Oral triptans have limitations in the treatment of some types of migraine. These include migraines associated with rapid onset of nausea and/or vomiting, migraines present on awakening, those that reach peak intensity rapidly or are severe at the time ...
Optimising the effect of dopaminergic treatment in Parkinson’s disease Presented by: Werner Poewe Department of Neurology, Medical University of Innsbruck, Austria In considering dopaminergic treatment of Parkinson’s disease (PD), one must consider dopaminergic drug targets, effect sizes of ...
Welcome to the latest edition of European Neurological Review, which features a wide range of topical articles covering several areas of neurology. We would like to begin by introducing our new Editor-in-Chief, Cris Constantinescu, whose knowledge and expertise will be ...
Migraine is the sixth most common form of disability globally that affects young, otherwise healthy subjects at the peak of their productive years.1 The management of chronic or refractory migraine with traditional pharmacological approaches can often prove challenging and unsatisfactory. ...
Neuromodulation (peripheral nerve neurostimulation [PNS] and central neurostimulation [CNS]) is a new promising treatment for headache disorders. PNS includes occipital nerve stimulation (ONS), vagal nerve stimulation (VNS), and stimulation that targets the supraorbital and sphenopalatine ganglion (SPG) stimulation. CNS includes ...
Epilepsy is one of the most common serious neurological conditions, has no geographic, social or racial boundaries and can affect people of all ages.1 It is frequently associated with co-morbidities, not just seizures, and is a condition that is linked ...
Seizures, paroxysmal neurological symptoms caused by episodic and pathologic neuronal discharging, have myriad associated signs/ symptoms that are dependent upon its anatomical origin and subsequent spread. The underlying causes of “epilepsy” (recurrent seizures) are many and include genetic factors, congenital ...
The last major breakthrough in the treatment of migraine and cluster headache (CH) began in the 1980s with the development of subcutaneous sumatriptan, which was introduced to the US market in 1993. Sumatriptan was life-changing for many individuals with migraine, and ...
Epilepsy is a general term used to describe a collection of common, chronic conditions of recurrent and unpredictable seizures. While seizures in newly diagnosed patients are often controlled with a single antiepileptic drug (AED),1 the estimated 30–40 % of patients who are ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
